News

Joined by leaders in Parkinson’s (PD) research and public policy, some 150 patients and advocates from across the nation will gather in Washington, D.C., on Monday for the 2019 Parkinson’s Policy Forum. The annual advocacy event, taking place Sept. 9–10, is presented this…

Trouble sleeping is incredibly frequent among people with Parkinson’s disease in Ethiopia, a new study suggests. Titled “Prevalence of sleep disorders in Parkinson’s disease patients in two neurology referral hospitals in Ethiopia,” the study was published in the journal BMC Neurology. Sleep disorders are common among…

Floor patterns with large, transverse visual cues may lessen freezing of gait  in patients with Parkinson’s, according to new research. The study, “Pavement Patterns Can Be Designed to Improve Gait in Parkinson’s Disease Patients,” was published in the journal Movement Disorders. A common feature…

Fatigue in Parkinson’s disease may be a clinical manifestation of low diastolic blood pressure — the second number presented in a BP measure, according to recent research. The study, “Fatigue in Parkinson’s Disease Associates with Lower Ambulatory Diastolic Blood Pressure,” was published in the Journal of…

Daily treatment with tablets of ENT-01, an investigational therapy for Parkinson’s disease, is safe and may restore patients’ bowel movements, according to results from Enterin‘s Phase 2a RASMET study. ENT-01 seems to locally stimulate a network of nerve cells that directs bowel function, suggesting that part of the nervous…

Following the positive results of a Phase 2a clinical trial, IRLAB Therapeutics is planning a Phase 2b/3 study for the first half of 2020 that will test IRL790 as an oral treatment candidate for Parkinson’s patients with levodopa-induced dyskinesia (LID) — involuntary, jerky movements that can…

Myobloc (rimabotulinumtoxinB) injections are approved by the U.S. Food and Drug Administration (FDA) to treat adults with chronic sialorrhea, or drooling, a condition often experienced by Parkinson’s patients. Myobloc, marketed by US WorldMeds, is the first botulinum toxin type B approved…

A new Phase 3 clinical trial, called the “BouNDless study,” will soon compare continuous administration of ND0612 to oral immediate-release carbidopa/levodopa (CD/LD) in people with Parkinson’s disease who are experiencing motor fluctuations, Mitsubishi Tanabe Pharma America (MTPA) announced. Both of the above-mentioned treatments work by increasing the level of…

A Phase 2 clinical trial of SEP-363856, an oral treatment candidate for patients with Parkinson’s psychosis, is recruiting participants throughout the U.S. The Sunovion-funded SEP361-203 study (NCT02969369) will be conducted at 24 U.S. sites and will include approximately 36 participants, 24 on SEP-363856 and 12…

The U.S Food and Drug Administration (FDA) has approved Kyowa Kirin’s Nourianz (istradefylline) tablets as an add-on therapy to treat off periods in Parkinson’s disease patients on a carbidopa/levodopa regimen. Off periods — when the effects of a medication wear off before a new dose can be…